

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH TYPE 2 DIABETES

1. **PL Detail-Document, Clinical Use of Metformin in Special Populations.** *Pharmacist's letter/prescriber's letter.* 2015.
2. Abe M, Kalantar-Zadeh K: **Haemodialysis-induced hypoglycaemia and glycaemic disarrays.** *Nat Rev Nephrol* 2015, **11**(5):302-313.
3. Amate JM, Lopez-Cuadrado T, Almendro N, Bouza C, Saz-Parkinson Z, Rivas-Ruiz R, Gonzalez-Canudas J: **Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis.** *International journal of clinical practice* 2015, **69**(3):292-304.
4. American Diabetes Association: **8. Pharmacologic Approaches to Glycemic Treatment.** *Diabetes Care* 2017, **40**(Suppl 1):S64-S74.
5. American Diabetes Association: **Standards of medical care in diabetes - 2017 abridged for primary care providers.** *Clin Diabetes* 2017, **35**(1):5-26.
6. American Diabetes Association: **9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019.** *Diabetes Care* 2019, **42**(Suppl 1):S90-S102.
7. Apotex Inc: **Apo-Tolbutamide.** *CA Product Monograph.* Weston, ON; 2010.
8. Arnason T, Mansell K: **Diabetes Mellitus. Therapeutics.** Edited by Jovaisas B. Ottawa (ON): Canadian Pharmacists Association; 2017.
9. AstraZeneca Canada Inc: **Bydureon (exenatide).** *CA Product Monograph.* Mississauga, ON; 2017.
10. AstraZeneca Pharmaceuticals LP: **Byetta (exenatide).** *US Product Monograph.* Wilmington, DE; 2015.
11. AstraZeneca Pharmaceuticals LP: **Onglyza (saxagliptin).** *US Product Monograph.* Wilmington, DE; 2018.
12. AstraZeneca Pharmaceuticals LP: **Bydureon (exenatide extended release).** *US Product Monograph.* Wilmington, DE; 2018.
13. AstraZeneca Pharmaceuticals LP: **Forxiga (dapagliflozin).** *US Product Monograph.* Wilmington, DE; 2018.
14. Baldwin D, Zander J, Munoz C, Raghu P, DeLange-Hudec S, Lee H, Emanuele MA, Glossop V, Smallwood K, Molitch M: **A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency.** *Diabetes Care* 2012, **35**(10):1970-1974.

15. Bayer HealthCare Pharmaceuticals Inc: **Precose (acarbose)**. *US Product Monograph*. Wayne, NJ; 2012.
16. Bayer Inc: **Glucobay (acarbose)**. *CA Product Monograph*. Toronto, ON; 2010.
17. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR: **Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis**. *Diabetes Care* 2008, **31**(11):2086-2091.
18. Boehringer Ingelheim (Canada) Ltd: **Jardiance (empagliflozin)**. *CA Product Monograph*. Burlington, ON; 2019.
19. Boehringer Ingelheim Pharmaceuticals Inc: **Tradjenta (linagliptin)**. *US Product Monograph*. Ridgefield, CT; 2017.
20. Boehringer Ingelheim Pharmaceuticals Inc: **Jardiance (empagliflozin)**. *US Product Monograph*. Ridgefield, CT; 2018.
21. Bristol-Myers Squibb: **Glucophage (metformin)**. *US Product Monograph*. Princeton, NJ; 2018.
22. British Columbia Guidelines and Protocols Advisory Committee: **Diabetes Care**. In. Edited by Association BCM. Victoria, BC: Guidelines and Protocols Advisory Committee; 2015.
23. Brunton S: **GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?** *International journal of clinical practice* 2014, **68**(5):557-567.
24. Canadian Agency for Drugs and Technologies in Health: **Guide to starting and adjusting insulin for Type 2 Diabetes**. *CADTH Reports*. Ottawa, Ontario: CADTH; 2012.
25. Canadian Agency for Drugs and Technologies in Health: **Second- and third-line pharmacotherapy for Type 2 Diabetes: Update**. In. Ottawa, ON: CADTH; 2013.
26. Canadian Agency for Drugs and Technologies in Health: **New drugs for Type 2 Diabetes: second-line therapy - recommendations report**. In., vol. 4: CADTH; 2017.
27. Canadian Diabetes Association Clinical Practice Guideline Expert Committee: **Appendix 5: Approximate cost reference list for antihyperglycemic agents**. *Canadian journal of diabetes* 2016, **40**(6).
28. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Imran SA, Rabasa-Lhoret R, Ross S: **Appendix 6: Therapeutic Considerations for Renal Impairment**. *Canadian journal of diabetes* 2013, **37 Suppl 1**:S207.
29. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Imran SA, Rabasa-Lhoret R, Ross S: **Appendix 3: Examples of insulin initiation and titration regimens in people with Type 2 Diabetes**. *Canadian journal of diabetes* 2013, **37 Suppl 1**:S200.

30. Canadian Diabetes Association: **Insulin initiation and titration suggestions for Type 2 Diabetes**. In.; 2014.
31. Canadian Pharmacists Association: **Sulfonylureas [CPhA monograph]**. RxTx. Ottawa, ON; 2015.
32. Castelan-Martinez OD, Hoyo-Vadillo C, Bazan-Soto TB, Cruz M, Tesoro-Cruz E, Valladares-Salgado A: **CYP2C9*3 gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide**. *Journal of clinical pharmacy and therapeutics* 2018, **43**(6):768-774.
33. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G: **Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial**. *Lancet (London, England)* 2013, **382**(9896):941-950.
34. Choi JH, Yee SW, Ramirez AH, Morrissey KM, Jang GH, Joski PJ, Mefford JA, Hesselson SE, Schlessinger A, Jenkins G *et al*: **A common 5'-UTR variant in MATE2-K is associated with poor response to metformin**. *Clinical pharmacology and therapeutics* 2011, **90**(5):674-684.
35. Depomed Inc: **Glumetza (metformin)**. *US Product Monograph*. Menlo Park, CA: Depomed; 2011.
36. Diabetes Canada Clinical Practice Guidelines Expert Committee: **Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada**. *Canadian journal of diabetes* 2018(42):S1-S325.
37. Diabetes Canada Clinical Practice Guidelines Expert Committee, Lipscombe L, Booth G, Butalia S, Dasgupta K, Eurich DT, Goldenberg R, Khan N, MacCallum L, Shah BR *et al*: **Pharmacologic Glycemic Management of Type 2 Diabetes in Adults**. *Canadian journal of diabetes* 2018, **42** Suppl 1:S88-S103.
38. Diabetes Genetics Replication Meta-analysis Consortium, Asian Genetic Epidemiology Network Type 2 Diabetes Consortium, South Asian Type 2 Diabetes Consortium, Mexican American Type 2 Diabetes Consortium, Type 2 Diabetes Genetic Exploration by Next-generation sequencing in multi-Ethnic Samples Consortium, Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ *et al*: **Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility**. *Nat Genet* 2014, **46**(3):234-244.
39. Dujic T, Zhou K, Yee SW, van Leeuwen N, de Keyser CE, Javorsky M, Goswami S, Zaharenko L, Hougaard Christensen MM, Out M *et al*: **Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Meta-Analysis**. *Clinical pharmacology and therapeutics* 2017, **101**(6):763-772.
40. Eli Lilly and Company: **Trulicity (dulaglutide)**. *US Product Monograph*. Indianapolis, IN; 2018.
41. Eli Lilly Canada Inc: **Humulin N (Insulin NPH)**. *CA Product Monograph*. Toronto, ON; 2016.

42. Eli Lilly Canada Inc: **Basaglar (Insulin glargine)**. *CA Product Monograph*. Scarborough, ON; 2016.
43. Eli Lilly Canada Inc: **Humalog (Insulin lispro)**. *CA Product Monograph*. Scarborough, ON; 2016.
44. Eli Lilly Canada Inc: **Trulicity (dulaglutide)**. *CA Product Monograph*. 2017.
45. Florez JC, Jablonski KA, Taylor A, Mather K, Horton E, White NH, Barrett-Connor E, Knowler WC, Shuldiner AR, Pollin TI: **The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program**. *Diabetes Care* 2012, **35**(9):1864-1867.
46. Franklin CS, Aulchenko YS, Huffman JE, Vitart V, Hayward C, Polasek O, Knott S, Zgaga L, Zemunik T, Rudan I *et al*: **The TCF7L2 diabetes risk variant is associated with HbA(1)(C) levels: a genome-wide association meta-analysis**. *Annals of human genetics* 2010, **74**(6):471-478.
47. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA *et al*: **Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm**. *Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists* 2019, **25**(1):69-100.
48. Gemini Laboratories LLC: **Prandin (repaglinide)**. *US Product Monograph*. Bridgewater, NJ; 2019.
49. Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, Sherifali D, Woo V, Yale JF: **Pharmacologic management of type 2 diabetes**. *Canadian journal of diabetes* 2013, **37 Suppl 1**:S61-68.
50. Henske JA, Griffith ML, Fowler MJ: **Initiating and titrating insulin in patients with Type 2 Diabetes**. *Clin Diabetes* 2009, **27**(2):72-76.
51. Holman RR BM, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group: **Effects of once-weekly Exenatide on cardiovascular outcomes in Type 2 Diabetes**. *The New England journal of medicine* 2017, **377**(13):1228-1239.
52. Holstein A, Hahn M, Korner A, Stumvoll M, Kovacs P: **TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes**. *BMC medical genetics* 2011, **12**:30.
53. Husain M BA, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC: **Oral Semaglutide and cardiovascular outcomes in patients with Type 2 Diabetes**. *The New England journal of medicine* 2019, **381**(9):841-851.
54. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK: **Metformin in patients with type 2 diabetes and kidney disease: a systematic review**. *Jama* 2014, **312**(24):2668-2675.

55. Janssen Inc: **Invokana (canagliflozin)**. *CA Product Monograph*. Toronto, ON; 2017.
56. Janssen Inc: **Invokana (canagliflozin)**. *CA Product Monograph*. Toronto, ON; 2019.
57. Janssen Pharmaceuticals Inc: **Invokana (canagliflozin)**. *US Product Monograph*. Titusville, NJ; 2018.
58. Janssen Pharmaceuticals Inc: **Invokana (canagliflozin)** *US Product Monograph*. Titusville, NJ; 2019.
59. Javorsky M, Klimcakova L, Schroner Z, Zidzik J, Babjakova E, Fabianova M, Kozarova M, Tkacova R, Salagovic J, Tkac I: **KCNJ11 gene E23K variant and therapeutic response to sulfonylureas**. *European journal of internal medicine* 2012, **23**(3):245-249.
60. Javorsky M, Babjakova E, Klimcakova L, Schroner Z, Zidzik J, Stolfova M, Salagovic J, Tkac I: **Association between TCF7L2 genotype and glycemic control in diabetic patients treated with gliclazide**. *Int J Endocrinol* 2013, **2013**:374858.
61. Kirchheiner J, Thomas S, Bauer S, Tomalik-Scharte D, Hering U, Doroshenko O, Jetter A, Stehle S, Tshauridu M, Meineke I *et al*: **Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype**. *Clinical pharmacology and therapeutics* 2006, **80**(6):657-667.
62. Lilly USA LLC: **Humulin N (human insulin)**. *US Product Monograph*. Indianapolis, IN; 2018.
63. Lipska KJ, Bailey CJ, Inzucchi SE: **Use of metformin in the setting of mild-to-moderate renal insufficiency**. *Diabetes Care* 2011, **34**(6):1431-1437.
64. Liu SC, Tu YK, Chien MN, Chien KL: **Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis**. *Diabetes, obesity & metabolism* 2012, **14**(9):810-820.
65. Marso SP BS, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T: **Semaglutide and cardiovascular outcomes in Patients with Type 2 Diabetes**. *The New England journal of medicine* 2016, **375**(19):1834-1844.
66. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS *et al*: **Liraglutide and cardiovascular outcomes in Type 2 Diabetes**. *The New England journal of medicine* 2016, **375**(4):311-322.
67. Marso SP, Holst AG, Vilsboll T: **Semaglutide and cardiovascular outcomes in patients with Type 2 Diabetes**. *The New England journal of medicine* 2017, **376**(9):891-892.
68. Mentz RJ, Thompson VP, Aguilar D, Choi J, Gustavson SM, Iqbal N, Kong AP, Ohman P, Sattar N, Scott RS *et al*: **Effects of once-weekly exenatide on clinical outcomes in patients with preexisting cardiovascular disease**. *Circulation* 2018, **138**(22):2576-2578.
69. Merck Sharp & Dohme Corp: **Januvia (sitagliptin)**. *US Product Monograph*. Whitehouse Station, NJ; 2018.

70. National Collaborating Centre for Chronic Conditions: **National Institute for Health and Clinical Excellence: Guidance.** *Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update)*. edn. London: Royal College of Physicians (UK), Royal College of Physicians of London.; 2008.
71. National Institute for Health and Care Evidence: **Empagliflozin in combination therapy for treating type 2 diabetes. [NICE Guideline TA336]**. In.; 2015.
72. National Institute for Health and Care Evidence: **Type 2 diabetes in adults: management. [NICE Guideline 28]** In.; 2015.
73. National Institute for Health and Care Excellence: **The management of type 2 diabetes. [NICE Guideline CG87]**. In.; 2014.
74. National Kidney Foundation: **KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.** *American journal of kidney diseases : the official journal of the National Kidney Foundation* 2012, **60**(5):850-886.
75. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondou N, Shaw W, Law G, Desai M, Matthews DR *et al*: **Canagliflozin and cardiovascular and renal events in Type 2 Diabetes.** *The New England journal of medicine* 2017, **377**(7):644-657.
76. Novo Nordisk Canada Inc: **GlucNorm (repaglinide).** *CA Product Monograph*. Mississauga, ON; 2015.
77. Novo Nordisk Canada Inc: **Levemir (insulin detemir).** *CA Product Monograph*. Mississauga, ON; 2017.
78. Novo Nordisk Canada Inc: **NovoRapid (insulin aspart).** *CA Product Monograph*. Mississauga, ON; 2018.
79. Novo Nordisk Canada Inc: **Ozempic (semaglutide).** *CA Product Monograph*. Mississauga, ON; 2018.
80. Novo Nordisk Inc: **Ozempic (semaglutide).** *US Product Monograph*. Plainsboro, NJ 2017.
81. Novo Nordisk Inc: **Victoza (liraglutide).** *US Product Monograph*. Wilmington, DE; 2018.
82. Novo Nordisk Inc: **Levemir (insulin detemir).** *US Product Monograph*. Plainsboro, NJ; 2019.
83. Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney AS, McCarthy MI, Hattersley AT, Morris AD, Palmer CN: **Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study.** *Diabetes* 2007, **56**(8):2178-2182.
84. Pedersen AJT, Stage TB, Glintborg D, Andersen M, Christensen MMH: **The pharmacogenetics of metformin in women with polycystic ovary syndrome: a randomized trial.** *Basic & clinical pharmacology & toxicology* 2018, **122**(2):239-244.

85. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S *et al*: **Canagliflozin and renal outcomes in Type 2 Diabetes and nephropathy**. *The New England journal of medicine* 2019, **380**(24):2295-2306.
86. Phani NM, Vohra M, Adhikari P, Nagri SK, Shashikiran U, D'Souza SC, Kalluri PRR, Satyamoorthy K, Rai PS: **Genetic variants identified from GWAS for predisposition to Type 2 Diabetes predict sulfonylurea drug response**. *Curr Mol Med* 2017, **17**(8):580-586.
87. Pharmacia and Upjohn Company LLC: **Glynase (glyburide)**. *US Product Monograph*. NY, NY; 2018.
88. Phung OJ, Scholle JM, Talwar M, Coleman CI: **Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes**. *Jama* 2010, **303**(14):1410-1418.
89. Regier L, Jensen B: **Anti-hyperglycemic agents**. *RxFiles drug comparison charts*. Saskatoon, SK: Saskatoon Health Region; 2017.
90. Reid T: **Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence**. *Clinical Diabetes* 2012, **30**(1):3-12.
91. Reid T, Gao L, Gill J, Stuhr A, Traylor L, Vlajnic A, Rhinehart A: **How much is too much? Outcomes in patients using high-dose insulin glargine**. *International journal of clinical practice* 2015.
92. Ren Q, Han X, Zhang S, Cai X, Ji L: **Combined influence of genetic variants and gene-gene interaction on sulfonylurea efficacy in Type 2 Diabetic patients**. *Exp Clin Endocrinol Diabetes* 2016, **124**(3):157-162.
93. Rubin DJ, Rybin D, Doros G, McDonnell ME: **Weight-based, insulin dose-related hypoglycemia in hospitalized patients with diabetes**. *Diabetes Care* 2011, **34**(8):1723-1728.
94. Sanchez-Ibarra HE, Reyes-Cortes LM, Jiang XL, Luna-Aguirre CM, Aguirre-Trevino D, Morales-Alvarado IA, Leon-Cachon RB, Lavalle-Gonzalez F, Morcos F, Barrera-Saldana HA: **Genotypic and phenotypic factors influencing drug response in Mexican patients with Type 2 Diabetes Mellitus**. *Front Pharmacol* 2018, **9**:320.
95. sanofi-aventis Canada Inc: **Amaryl (glimepiride)**. *CA Product Monograph*. Laval, QC; 2016.
96. sanofi-aventis Canada Inc: **Diabeta (glyburide)**. *CA Product Monograph*. Laval, QC; 2016.
97. sanofi-aventis Canada Inc: **Lantus (insulin glargine)**. *CA Product Monograph*. Laval, QC; 2017.
98. sanofi-aventis Canada Inc: **Apidra (insulin glulisine)**. *CA Product Monograph*. Laval, QC; 2017.
99. sanofi-aventis US LLC: **Diabeta (glyburide)**. *US Product Monograph*. Bridgewater, NJ; 2016.
100. sanofi-aventis US LLC: **Lantus (insulin glargine)**. *US Product Monograph*. Bridgewater, NJ; 2018.

101. sanofi-aventis US LLC: **Amaryl (glimepiride)**. *US Product Monograph*. Bridgewater, NJ; 2018.
102. Scheen AJ, Paquot N: **Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes**. *Diabetes & metabolism* 2013, **39**(3):179-190.
103. Scherthner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, Kawaguchi M, Canovatchel W, Meininger G: **Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial**. *Diabetes Care* 2013, **36**(9):2508-2515.
104. Schroner Z, Javorsky M, Tkacova R, Klimcakova L, Dobrikova M, Habalova V, Kozarova M, Zidzik J, Rudikova M, Tkac I: **Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes**. *Diabetes, obesity & metabolism* 2011, **13**(1):89-91.
105. Scottish Intercollegiate Guidelines Network (SIGN): **Management of diabetes**. In. Edinburgh: SIGN; 2010.
106. Servier Canada Inc: **Diamicron MR (gliclazide MR)**. *CA Product Monograph*. Laval, QC; 2016.
107. Servier Canada Inc: **Diamicron (gliclazide)**. *CA Product Monograph*. Laval, QC; 2016.
108. Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, Gnasso A, Grupillo M, Lauro R, Hribal ML *et al*: **The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes**. *The Journal of clinical endocrinology and metabolism* 2006, **91**(6):2334-2339.
109. Shionogi Inc: **Fortamet (metformin hydrochloride xr)**. *US Product Monograph*. Florham Park, NJ; 2017.
110. Shokri F, Ghaedi H, Ghafouri Fard S, Movafagh A, Abediankenari S, Mahrooz A, Kashi Z, Omrani MD: **Impact of ATM and SLC22A1 polymorphisms on therapeutic response to metformin in Iranian diabetic patients**. *International journal of molecular and cellular medicine* 2016, **5**(1):1-7.
111. Srinivasan S, Kaur V, Chamarthi B, Littleton KR, Chen L, Manning AK, Merino J, Thomas MK, Hudson M, Goldfine A *et al*: **TCF7L2 genetic variation augments incretin resistance and influences response to a sulfonylurea and metformin the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH)**. *Diabetes Care* 2018, **41**(3):554-561.
112. Stage TB, Christensen MM, Feddersen S, Beck-Nielsen H, Broesen K: **The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARGgamma on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes**. *Pharmacogenetics and genomics* 2013, **23**(4):219-227.
113. Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A, Ramirez AH, Roden DM, Wilke RA, McCarty CA *et al*: **The effect of novel promoter variants in MATE1 and MATE2 on the**

- pharmacokinetics and pharmacodynamics of metformin.** *Clinical pharmacology and therapeutics* 2013, **93**(2):186-194.
114. Sun Pharmaceutical Industries Inc: **Riomet (metformin).** *US Product Monograph.* Cranbury, NJ; 2018.
 115. Takeda Canada Inc: **Actos (pioglitazone hydrochloride).** *CA Product Monograph.* Mississauga, ON; 2018.
 116. Takeda Pharmaceuticals America Inc: **Nesina (alogliptin).** *US Product Monograph.* Deerfield, IL; 2016.
 117. Takeda Pharmaceuticals America Inc: **Actos (pioglitazone).** *US Product Monograph.* Deerfield, IL; 2017.
 118. Tong Y, Lin Y, Zhang Y, Yang J, Zhang Y, Liu H, Zhang B: **Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis.** *BMC medical genetics* 2009, **10**:15.
 119. van Leeuwen N, Nijpels G, Becker ML, Deshmukh H, Zhou K, Stricker BH, Uitterlinden AG, Hofman A, van 't Riet E, Palmer CN *et al*: **A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts.** *Diabetologia* 2012, **55**(7):1971-1977.
 120. Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Orsted DD *et al*: **Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke.** *Circulation* 2018, **138**(25):2884-2894.
 121. Wang J, Hu F, Feng T, Zhao J, Yin L, Li L, Wang Y, Wang Q, Hu D: **Meta-analysis of associations between TCF7L2 polymorphisms and risk of type 2 diabetes mellitus in the Chinese population.** *BMC medical genetics* 2013, **14**:8.
 122. Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, Hawley SA, Donnelly LA, Schofield C, Groves CJ *et al*: **Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.** *Nat Genet* 2011, **43**(2):117-120.
 123. Zhou K, Yee SW, Seiser EL, van Leeuwen N, Tavendale R, Bennett AJ, Groves CJ, Coleman RL, van der Heijden AA, Beulens JW *et al*: **Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.** *Nat Genet* 2016, **48**(9):1055-1059.
 124. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ *et al*: **Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes.** *The New England journal of medicine* 2015, **373**(22):2117-2128.